Kiniksa Pharmaceuticals, Ltd. — Q3 2019 Form 10-Q
Reporting period: Three and nine months ended September 30, 2019; balance-sheet comparisons are with December 31, 2018. The filing identifies the registrant as Kiniksa Pharmaceuticals, Ltd. (Bermuda), a clinical-stage biopharmaceutical company. Amounts below are in U.S. dollars; financial-statement amounts reported in thousands are shown in millions.
Business context and financial results
Kiniksa develops therapies for autoinflammatory and autoimmune conditions. Its candidates include rilonacept, mavrilimumab, KPL-716, KPL-404 and KPL-045. The company had no approved products and generated no product revenue.
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $22.0m | $20.6m | $112.1m | $50.5m |
| General and administrative expense | $8.4m | $5.5m | $25.3m | $13.6m |
| Total operating expenses | $30.4m | $26.2m | $137.4m | $64.0m |
| Interest income | $1.4m | $1.6m | $4.9m | $3.0m |
| Income-tax benefit | $2.0m | $0.1m | $2.4m | $0.4m |
| Net loss | $27.1m | $24.4m | $130.1m | $60.6m |
| Net loss per share, basic and diluted | $0.49 | $0.51 | $2.42 | $2.62 |
Profitability and operating margins are not meaningful because the company reported no revenue. At September 30, cash and cash equivalents were $68.8m and short-term investments were $189.9m, for combined liquidity of $258.7m. Current assets were $268.3m versus current liabilities of $27.6m. Total liabilities were $29.9m; the balance sheet reports no borrowings. Shareholders’ equity was $251.9m, down from $279.3m at year-end 2018.
For the first nine months, operating cash outflow was $134.2m, investing activities provided $47.3m (largely net maturities of Treasury investments), and financing activities provided $83.7m. Cash, cash equivalents and restricted cash decreased $3.2m to $69.0m. The company raised $83.0m net from a February follow-on offering and concurrent private placement. No cash dividends were declared or paid.
Material changes versus prior periods
- Q3 net loss increased $2.7m year over year, while nine-month net loss increased $69.4m. Nine-month operating expenses rose $73.4m, primarily reflecting expanded clinical and development activity and higher staffing and public-company costs.
- Nine-month R&D included $18.0m related to the Primatope acquisition of KPL-404 and a $10.0m Biogen clinical milestone for KPL-716. Kiniksa expensed the acquired in-process research and development because it had no alternative future use.
- R&D spending by program for the first nine months rose to $19.8m for rilonacept, $11.5m for mavrilimumab, $25.5m for KPL-716 and $21.8m for KPL-404. Unallocated R&D costs also increased as personnel and laboratory operations expanded.
- The company adopted the new lease standard on January 1, 2019, recording lease right-of-use assets and liabilities. At September 30, operating lease liabilities totaled $3.0m.
Outlook, risks and contingencies
- Management expected existing cash, cash equivalents and short-term investments to cover operating expenses and capital expenditures for at least 12 months from the financial-statement issuance date. The filing states that continued viability beyond that period depends on raising additional capital; the estimate relies on assumptions and funds could be used sooner than expected.
- Management expected significant operating losses to continue for the foreseeable future as clinical programs advance. It provided no revenue or earnings guidance.
- Key stated trial milestones: top-line RHAPSODY Phase 3 rilonacept data and mavrilimumab Phase 2 data were expected in the second half of 2020; KPL-716 prurigo nodularis and exploratory chronic-pruritus data were expected in the first half of 2020; KPL-404 Phase 1 data were expected in the second half of 2020. Kiniksa planned to present final data from its rilonacept Phase 2 study at the American Heart Association Scientific Sessions in November 2019.
- Principal risks include clinical-trial delay or failure, safety and regulatory hurdles, patient enrollment, manufacturing and single-source supplier dependence, competition, intellectual-property protection, and the need for additional financing. Kiniksa noted that mavrilimumab’s risk-benefit assessment may depend on patient population and that longer-duration safety and efficacy evidence may be needed.
- Commitments included $5.4m of minimum payments under manufacturing agreements at September 30, 2019, plus contingent license milestones, royalties and other contractual obligations. The company reported no material legal proceedings and no litigation contingency reserve.
- Class B shares carried ten votes per share; management held approximately 66% of aggregate voting power at September 30, 2019. The filing also describes conversion rights that could materially shift voting control. Disclosure controls were deemed effective at the reasonable-assurance level, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Whether the stated 12-month liquidity runway remains supported by the current operating plan and actual cash burn.
- Enrollment, execution, safety and eventual top-line results for RHAPSODY and the other clinical programs, against the timelines stated in the filing.
- The composition of the $28.0m in Primatope and Biogen milestone-related R&D expense, and the timing and conditions of remaining milestone and manufacturing commitments.
- Manufacturing capacity and supply continuity, including reliance on third parties and single-source suppliers.
- Potential dilution from future financing and the effects of the multi-class share structure and conversion rights on voting control.